CA2284170A1 - Identification of agents for use in the treatment of alzheimer's disease - Google Patents

Identification of agents for use in the treatment of alzheimer's disease Download PDF

Info

Publication number
CA2284170A1
CA2284170A1 CA002284170A CA2284170A CA2284170A1 CA 2284170 A1 CA2284170 A1 CA 2284170A1 CA 002284170 A CA002284170 A CA 002284170A CA 2284170 A CA2284170 A CA 2284170A CA 2284170 A1 CA2284170 A1 CA 2284170A1
Authority
CA
Canada
Prior art keywords
alzheimer
disease
treatment
identification
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002284170A
Other languages
French (fr)
Other versions
CA2284170C (en
Inventor
Ashley I. Bush
Xudong Huang
Craig S. Atwood
Rudolph E. Tanzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
The General Hospital Corporation
Ashley I. Bush
Xudong Huang
Craig S. Atwood
Rudolph E. Tanzi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corporation, Ashley I. Bush, Xudong Huang, Craig S. Atwood, Rudolph E. Tanzi filed Critical The General Hospital Corporation
Publication of CA2284170A1 publication Critical patent/CA2284170A1/en
Application granted granted Critical
Publication of CA2284170C publication Critical patent/CA2284170C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)

Abstract

The invention relates to the identification of pharmacological agents to be used in the treatment of Alzheimer's disease and related pathological conditions. Methods and compositions for treatment of conditions caused by amyloidosis, A.beta.-mediated ROS formation, or both, such as Alzheimer's disease, are disclosed.
CA002284170A 1997-03-11 1998-03-11 Identification of agents for use in the treatment of alzheimer's disease Expired - Fee Related CA2284170C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81612297A 1997-03-11 1997-03-11
US08/816,122 1997-03-11
PCT/US1998/004683 WO1998040071A1 (en) 1997-03-11 1998-03-11 Identification of agents for use in the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
CA2284170A1 true CA2284170A1 (en) 1998-09-17
CA2284170C CA2284170C (en) 2008-12-02

Family

ID=25219748

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002284170A Expired - Fee Related CA2284170C (en) 1997-03-11 1998-03-11 Identification of agents for use in the treatment of alzheimer's disease

Country Status (5)

Country Link
EP (1) EP1007048A4 (en)
JP (1) JP2001514661A (en)
AU (1) AU748768B2 (en)
CA (1) CA2284170C (en)
WO (1) WO1998040071A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743771B2 (en) * 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
EA002526B1 (en) 1997-08-21 2002-06-27 П.Н.Геролиматос С.А. Use of phanquinone for the treatment of alzheimer's disease
WO1999018432A1 (en) 1997-10-06 1999-04-15 The General Hospital Corporation Methods for screening drugs to predict tardive dyskinesia
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6638711B1 (en) * 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
WO2000018392A1 (en) 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine oxidase: antagonists and inhibitors
DK1140090T3 (en) 1999-01-07 2005-04-18 Gerolymatos P N Sa Use of phanquinone for the treatment or prevention of memory failure
DE19909357A1 (en) * 1999-03-03 2000-09-07 Gerd Multhaup Copper agonist that binds to the APP copper binding site and / or has an inhibitory effect on the release of the amyloid-Aß peptide
EP1200470B1 (en) * 1999-08-04 2004-11-24 The University Of Southern California Globular assembly of amyloid beta protein and uses thereof
US20030138374A1 (en) * 2000-03-22 2003-07-24 Yukitsuda Kudo Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same
AUPR976401A0 (en) * 2001-12-27 2002-01-31 Alzhyme Pty Ltd Agents for the treatment of alzheimer's disease and screening methods for the same
AU2002351880B2 (en) * 2001-12-27 2007-08-30 Neuroscientific Biopharmaceuticals Pty Ltd Screening methods and the use of agents identified using the same
JP4860906B2 (en) 2002-03-08 2012-01-25 プロテミックス コーポレイション リミティド Prevention and / or treatment of heart disease and / or related heart failure
WO2004017956A1 (en) 2002-08-20 2004-03-04 Protemix Corporation Limited Dosage forms and related therapies
JP2006520768A (en) * 2003-03-21 2006-09-14 パリュメ エス アー Nitrogen-containing polycyclic derivatives useful as chelating agents for metal ions and their uses
CA2536393A1 (en) * 2003-09-09 2005-06-16 Gilead Sciences, Inc. Use of liposomes which are small unilamellar vesicles for the removal of an entity from a biological sample
US20050159364A1 (en) * 2003-12-19 2005-07-21 Cooper Garth J. Copper antagonist compounds
US7582796B2 (en) 2004-07-19 2009-09-01 Protemix Corporation Limited Synthesis of triethylenetetramines
GEP20105110B (en) 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
EP2380983A3 (en) 2006-05-05 2012-12-05 TransTech Pharma Inc. RAGE fusion proteins, formulations, and methods of use thereof
US8338089B2 (en) 2006-11-20 2012-12-25 The Johns Hopkins University Method of inhibiting lentiviral infectivity utilizing zinc chelation to inhibit Vif activity
RU2513695C2 (en) 2007-06-14 2014-04-20 Гэлэктика Фармасьютикалс, Инк. Fused rage proteins
WO2009108999A1 (en) 2008-03-03 2009-09-11 Ross Stewart Grant Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
CA2757079C (en) 2009-04-20 2015-05-19 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
WO2018236221A2 (en) * 2017-06-03 2018-12-27 Can Holding B.V. Neurodegenerative peptide deposit dissolution
KR102048846B1 (en) * 2017-11-20 2019-11-27 한국생명공학연구원 Medicine for treating vascular disease and method for screening the same
JPWO2021015300A1 (en) * 2019-07-25 2021-01-28

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434050A (en) * 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
AU669493B2 (en) * 1991-11-12 1996-06-13 University Of Melbourne, The A method for assaying and treating Alzheimer's disease
US5688516A (en) * 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
JPH07149668A (en) * 1993-11-30 1995-06-13 Kanegafuchi Chem Ind Co Ltd Substance for detecting amyloid deposit
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
ATE218583T1 (en) * 1995-03-14 2002-06-15 Praecis Pharm Inc COMPOUNDS WITH AGGREGATION-MODULATING EFFECTS ON AMYLOID PROTEIN
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases

Also Published As

Publication number Publication date
WO1998040071A1 (en) 1998-09-17
AU748768B2 (en) 2002-06-13
EP1007048A4 (en) 2004-09-22
JP2001514661A (en) 2001-09-11
CA2284170C (en) 2008-12-02
EP1007048A1 (en) 2000-06-14
AU6548498A (en) 1998-09-29

Similar Documents

Publication Publication Date Title
CA2284170A1 (en) Identification of agents for use in the treatment of alzheimer's disease
CA2323458A1 (en) Metal chelators for use in the treatment of alzheimer's disease
CA2289531A1 (en) Composition and methods for treating alzheimer's disease and other amyloidoses
AU2002219824A1 (en) Compositions and methods for diagnosing alzheimer's disease
HUP0103654A2 (en) Use of smilagenin and anzurogenin-d for production of pharmaceutical compositions for the treatment of alzheimer's disease
WO1998022494A3 (en) METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
AU1407399A (en) Treatment for alzheimer's disease
ZA968476B (en) Cleansing compositions with dendrimers as mildness agents.
AU3113500A (en) Compositions for treating alzheimer's disease and other amyloidoses
CA2311356A1 (en) Method for treating alzheimer's disease
ZA977310B (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease.
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
CA2290101A1 (en) Tourmaline in cosmetic cleansing compositions
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
NO20001869D0 (en) Procedures for the treatment of Alzheimer's disease
DE59504401D1 (en) St. John's wort extracts
CA2301706A1 (en) Use of phanquinone for the treatment of alzheimer's disease
AU3068899A (en) Diagnostic assay for late-onset alzheimer's disease
AU1405899A (en) Treatment for alzheimer's disease
PL345697A1 (en) Method for the production of n,n'-carbonyl diazoles
AU2001248760A1 (en) Preventives/remedies for alzheimer's disease
DE69805988D1 (en) PREPARATION OF 1,3-DIAMINOPENTANE BY HYDROGENATING 3-AMINOPENTANITRILE
ZA971716B (en) 1,1,2-triphenylbut-1-ene derivatives for treating alzheimer's disease
EP1181550A4 (en) Methods for the identification of compounds for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed